Business
Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes
Beckman Coulter Diagnostics, a Danaher company and global leader in clinical diagnostics, today announced it has received CE 2797 mark under IVDR for the Access MeMed BV assay, enabling broad availability of a high-throughput host‑response test that helps clinicians differentiate between bacterial and viral infections in approximately 20 minutes.
About this update from Danaher Corporation
[{"type":"text","content":"Modeling Shows Adoption of New Access MeMed BV Assay Could Cut up to €80M in Avoidable Costs across European Health Systems through Fewer Unnecessary Admissions and Testing","length":177,"tagName":"p","attribs":{}},{"type":"text","content":"BREA, Calif., April 13, 2026 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and global leader in clinical diagnostics, today announced it has received CE 2797 mark under IVDR for the Access MeMed BV assay, enabling broad availability of a high-throughput host‑response test that helps clinicians differentiate between bacterial and viral infections in approximately 20 minutes.","length":398,"tagName":"p"},{"type":"image","alt":"A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory’s role in improving patient health for more than 80 years. (PRNewsfoto/Beckman Coulter Diagnostics)","displaySize":"","headline":null,"caption":"A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory’s role in improving patient health for more than 80 years. (PRNewsfoto/Beckman Coulter Diagnostics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":115,"url":"https://media.zenfs.com/en/prnewswire.com/eb94e0aa5ba53c8ca4b37741e42d9a58"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kGnAB0_tRzGVzJObu2UV4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIwMw--/https://media.zenfs.com/en/prnewswire.com/eb94e0aa5ba53c8ca4b37741e42d9a58","width":400,"height":115}},"href":"https://mma.prnewswire.com/media/2329111/Beckman_Coulter_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Validated for use across Beckman Coulter's installed base of DxI 9000 and Access 2 immunoassay analyzers, the Access MeMed BV assay enables fast, reliable infection differentiation while leveraging laboratories' existing infrastructure and workflows. Beckman Coulter partnered with MeMed, a leader in advanced host‑response technologies, to bring the proven MeMed BV® test into core laboratory settings. The MeMed BV test has been shown to enhance clinical decision‑making, support clinicians in curbing unnecessary antibiotic use, and advance antimicrobial‑stewardship initiatives—results reinforced by strong clinical studies and real‑...